ஜர்னல் ஆஃப் கிளினிக்கல் கேஸ் ரிப்போர்ட்ஸ்

Paclitaxel-Related Lymphedema and Scleroderma-Like Skin Changes

Abstract

Fany Colson, Berline Sigha, Jorge E Arrese, Pascale Quatresooz, Rorive A, Collignon J and Arjen F Nikkels

Paclitaxel is an antimicrotubule agent used for the treatment of metastatic breast cancer. The development of scleroderma-like skin changes is an exceptional adverse effect. We report two patients with metastatic breast cancer treated by paclitaxel who presented an unexplained unilateral lymphedema of the upper limb. Medical work-up did not demonstrate any mechanical or tumor obstruction of the lymphatic vessels. Dermatologic examination revealed cutaneous and subcutaneous indurations and hardening of certain areas of the involved arm. The clinical suspicion of scleroderma was confirmed by histology and immunohistology. Treatment was initiated with methotrexate and methylprednisolone, resulting in a clear reduction of the lymphedema and a regression of the scleroderma. These two cases suggest a pathogenic role of paclitaxel-induced scleroderma in the subsequent development of severe localized lymphedema.